Marinus Pharmaceuticals (NASDAQ:MRNS) shares are trading higher on Thursday after the company announced it has received FDA rare pediatric disease designation for Ganaxolone for the treatment of CDKL5 deficiency disorder.
Marinus Pharmaceuticals is a clinical stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychiatric therapeutics.
The company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19 pediatric epilepsy.
Marinus Pharmaceuticals shares were trading up 6.29% at $1.69 at time of publication on Thursday. The stock has a 52-week high of $3.50 and a 52-week low of $1.01.